Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Biochem Biophys Res Commun ; 675: 33-40, 2023 10 01.
Article in English | MEDLINE | ID: mdl-37451215

ABSTRACT

Colorectal cancer is one of the most common cancers worldwide, affecting the colon and rectum. A major problem in the treatment of colorectal cancer is acquired chemoresistance, including resistance against death receptor-induced apoptosis. Therefore, investigating new biomarkers for the treatment of the disease and sensitization strategies against TRAIL might be of high clinical importance. TNFRSF10A/B are known as death receptors for TRAIL-induced apoptotic cell death. In this study, we used multiple bioinformatic tools and experimental analyses to investigate the role of TRAIL receptors TNFRSF10A and TNFRSF10B in colorectal cancer. We also identified the potential effect of bortezomib and epirubicin in the induction of TRAIL-mediated apoptotic cell death. Here, we showed that TNFRSF10 A/B expressions are upregulated in various tumor types, including COAD, and its high expression is decreased with the different clinicopathological parameters in COAD. We also found an association between TNFRSF10 A/B expression and tumor molecular subtypes. We further detected the association between the expression of TNFRSF10 A/B and immune cell tumor infiltration, including B cells, CD8+ T cells, neutrophils and dendritic cells. In addition, we showed that combining bortezomib and epirubicin treatment leads to the upregulation of TNFRSF10 A/B in colorectal cancer cells in vitro. The increase in the expression of death receptors was correlated with higher active caspase-3 levels following the incubation of cells with recombinant TRAIL protein, which is a ligand for TNFRSF10 A/B receptors. Our results suggest that TNFRSF10 A/B may be a marker to differentiate tumor molecular subtypes in colorectal cancer. The expression of TNFRSF10 A/B may be associated with the recruitment of immune cells into tumors and the development of tumor suppression. The combination of bortezomib and epirubicin treatment might sensitize colorectal cancer cells to TRAIL-induced apoptosis via the upregulation of death receptor.


Subject(s)
CD8-Positive T-Lymphocytes , Colorectal Neoplasms , Humans , Apoptosis , Bortezomib/pharmacology , CD8-Positive T-Lymphocytes/metabolism , Cell Line, Tumor , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/metabolism , Epirubicin/pharmacology , Receptors, TNF-Related Apoptosis-Inducing Ligand/metabolism , TNF-Related Apoptosis-Inducing Ligand/metabolism
2.
Insects ; 13(2)2022 Feb 03.
Article in English | MEDLINE | ID: mdl-35206735

ABSTRACT

The use of synthetic insecticides has been a solution to reduce mosquito-borne disease transmission for decades. Currently, no single intervention is sufficient to reduce the global disease burden caused by mosquitoes. Problems associated with extensive usage of synthetic compounds have increased substantially which makes mosquito-borne disease elimination and prevention more difficult over the years. Thus, it is crucial that much safer and effective mosquito control strategies are developed. Natural compounds from plants have been efficiently used to fight insect pests for a long time. Plant-based bioinsecticides are now considered a much safer and less toxic alternative to synthetic compounds. Here, we discuss candidate plant-based compounds that show larvicidal, adulticidal, and repellent properties. Our discussion also includes their mode of action and potential impact in mosquito disease transmission and circumvention of resistance. This review improves our knowledge on plant-based bioinsecticides and the potential for the development of state-of-the-art mosquito control strategies.

SELECTION OF CITATIONS
SEARCH DETAIL
...